Zydus Bets Big on Affordable GLP-1 Therapy With New Semaglutide Brands in India

Ahmedabad-basedZydus Lifesciences Limitedis set to make a major move in the IndianGLP-1 therapymarket with the launch of its genericsemaglutide injectionimmediately after the drug’s patent expires in late March 2026 — a strategy that could significantly expand access to advanced diabetes...